Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry

Current Medical Research and Opinion

Volumn 28, Issue 3, 2012, Pages 419-428

  Baser, Onur ^a,b   Wei, Wenhui ^c   Henk, Henry J ^d   Teitelbaum, April ^d   Xie, Lin ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b STATINMED RESEARCH   (United States)

^c SANOFI   (France)

^d Innovus   (United States)

Author keywords

Costs; Health insurance claims; Retrospective observational study; Triple negative breast cancer; Utilization

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GROWTH FACTOR; METHOTREXATE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MANAGED CARE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; REIMBURSEMENT; RESOURCE ALLOCATION; SOCIAL SECURITY; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; UNITED STATES;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; COHORT STUDIES; DELIVERY OF HEALTH CARE; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84858174379     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.628649     Document Type: Article

References (32)

1. Ferlay J, Shin HR, Bray F, et al. Cancer incidence and mortality worldwide: IARC CancerBase No. 10. GLOBOCAN 2008. Lyon, France: International Agency for Research on Cancer, 2010. Available at: Http://globocan.iarc.fr [Last accessed 24 November 2010]
2. SEER Statistics Fact Sheets: Breast. Bethesda, MD: National Cancer Institute, 2010. Available at: Http://seer.cancer.gov/statfacts/html/breast.html [Last accessed 9 November 2010]
3. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009;27:1168-76
4. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7:e1000279
5. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48
6. Carey L, Winer E, Viale G, et al. Triple-negative breast cancer:disease entity or title of convenience? Nat Rev Clin Oncol 2010;7:683-92
7. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26:4282-8
8. Chacón RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010;12(Suppl 2):S3
9. Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009;9:86
10. Reis-Filho JS, Tutt AN. Triple negative tumours: A critical review. Histopathology 2008;52:108-18
11. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2- negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer 2007;109:1721-8
12. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34
13. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81
14. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. Cancer 2008;113:2638-45
15. Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010;3:42
16. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009;9 (Suppl 2):S73-81
17. Postmarket Drug Safety Information for Patients and Providers. Avastin (bevacizumab) Information. Rockville, MD: US Food and Drug Administration. Updated 18 January 2011. Available at: Http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformation for PatientsandProviders/ucm193900.htm [Last accessed 9 November 2010]
18. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364:205-14.
19. Baselga J, Gomez P, Awada A, et al. The addition of cetuximab to cisplatin increases overall response rate (orr) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II study (BALI-1) [ESMO abstract 2740]. Ann Oncol 2010; 21(Suppl 8):viii96-viii121
20. Onitilo AA, Engel JM, Greenlee RT, et al. Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13
21. Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999- 2008, Medical Care. Series ID: SUUR0000SAM. Consumer Price Index. Washington, DC: US Department of Labor, Bureau of Labor Statistics, 2008. Available at: Http://data.bls.gov/cgi-bin/surveymost?su [Last accessed 5 January 2011]
22. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
23. Basér O, Gardiner JC, Bradley CJ, et al. Longitudinal analysis of censored medical cost data. Health Econ 2006;15:513-25
24. Basér O, Gardiner J, Bradley C, et al. Estimation from censored medical cost data. Biometrical J 2004;46:351-63
25. Lin DY. Linear regression analysis of censored medical costs. Biostatistics 2000;1:35-47
26. Hendricks A, Gardner J, Frakt A, et al. What can Medicaid data add to research on VA patients? J Rehabil Res Dev 2010;47:773-80
27. Yamamoto K, Matsumoto S, Tada H, et al. A data capture system for outcomes studies that integrates with electronic health records: Development and potential uses. J Med Syst 2008;32:423-7
28. Atreja A, Achkar JP, Jain AK, et al. Using technology to promote gastrointestinal outcomes research: A case for electronic health records. Am J Gastroenterol 2008;103:2171-8
29. Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008;100:888-97
30. Barron JJ, Quimbo R, Nikam PT, et al. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat 2008;109:367-77
31. Dahlberg L, Lundkvist J, Lindman H. Health care costs for treatment of disseminated breast cancer. Eur J Cancer 2009;45:1987-91
32. Lamerato L, Havstad S, Gandhi S, et al. Economic burden associated with breast cancer recurrence: Findings from a retrospective analysis of health system data. Cancer 2006;106:1875-82